GSTM1 and chronic kidney disease: In the Hb < 11 g/dL ESA-treated cohort, the proportion of patients receiving short-acting ESAs decreased with CKD stage from 69.6% to 54.0%, in favour of long-acting ESAs (the proportion of patients increased from 36.1% for stage 3a to 63.7% for stage 5).